H. Wilkins Biography and Net Worth

Dr. Wilkins brings over 19 years of clinical research experience to Avalo Therapeutics, most recently serving as Chief Medical Officer of Zyla Life Sciences. Previously, he held the position of Chief Medical Officer at Onspira Therapeutics, Lycera, and Ceptaris Therapeutics, Inc., where he led clinical programs from IND phase 1 trials to regulatory approval (including Valchlor®). Prior to this, Dr. Wilkins was Vice President, Worldwide Clinical Research, Inflammation/Oncology at Cephalon Inc., where he led clinical development, medical affairs, and business development efforts in both therapeutic areas. Previously, he was Senior Vice President of Clinical Development with Ception Therapeutics, where he headed a successful program in eosinophilic asthma prior to the company’s acquisition by Cephalon. Dr. Wilkins entered the pharmaceutical industry with GlaxoSmithKline (GSK), where he rose to become Vice President of Discovery Medicine for GSK’s Center of Excellence in External Drug Discovery. He also served as Group Director of GSK’s urology franchise, responsible for Levitra® and the launch of VESIcare®. Earlier in his career as a practicing primary care physician, Dr. Wilkins was Co-Founder and Chief Executive Officer of TriValley Primary Care, a large multicenter primary care group in Southeastern Pennsylvania. Dr. Wilkins received his BS from Bucknell University and his MD from Temple University School of Medicine.